A case of malignant melanoma with retinal detachment due to dabrafenib and trametinib therapy
Author:
Affiliation:
1. Department of Dermatology, Dokkyo University School of Medicine
2. Department of Ophthalmology, Dokkyo University School of Medicine
Publisher
The Japanese Skin Cancer Society
Link
https://www.jstage.jst.go.jp/article/skincancer/37/1/37_7/_pdf
Reference6 articles.
1. 1) Vultur A, Villanueva J, Herlyn M : Targeting BRAF in advanced melanoma : a first step toward manageable disease. Clin Cancer Res, 17:1658－1663, 2011
2. 2) King AJ, Arnone MR, Bleam MR, et al : Dabrafenib ; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS One, 8 : e67583, 2013
3. 3) Stjepanovic N, Velazquez－Martin JP, Bedard PL : Ocular toxicities of MEK inhibitors and other targeted therapies. Annals of Oncology, 27 : 998－1005, 2016
4. 4) Merissa LW, Michelle CL, Keith TF, et al : Subretinal fluid associated with MEK inhibitor use in the treatment of systemic cancer. JAMA Ophthalmol, 134 : 855－862, 2016
5. 5) NOVARTIS社内資料：海外第III相臨床試験（MEK 116513試験）
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3